Home  /  Resource Library  /  Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Results of a trial examining rituximab, lenalidomide and ibrutinib for first line treatment of DLBCL.